Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Perfuse Therapeutics Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, so the available docket follows a single examination path.
BASQUILL, SEAN M is the busiest identified examiner, with 1 pending matter. The concentrated structure supports direct file-level management. Counsel can focus on the biotechnology and pharmaceutical disclosure, the claims under examination, and a response tailored to the identified examiner’s art-unit context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19397828 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | BASQUILL, SEAN M | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19397828 | TREATMENT OF DIABETIC RETINOPATHY USING ENDOTHELIN RECEPTOR ANTAGONISTS | BASQUILL, SEAN M | 1614 | §103 | Final Rejection | — | Pending | Nov 21, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPerfuse Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean M Basquill has the most, with 1 of Perfuse Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
